AR061804A1 - Inhibidores de tirosina quinasa - Google Patents
Inhibidores de tirosina quinasaInfo
- Publication number
- AR061804A1 AR061804A1 ARP070102972A ARP070102972A AR061804A1 AR 061804 A1 AR061804 A1 AR 061804A1 AR P070102972 A ARP070102972 A AR P070102972A AR P070102972 A ARP070102972 A AR P070102972A AR 061804 A1 AR061804 A1 AR 061804A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- cycloalkyl
- alkenyl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 abstract 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005275 alkylenearyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Son utiles para tratar enfermedades proliferativas celulares, para tratar trastornos asociados con actividad MET, y para inhibir la tirosina quinasa de receptor MET. Se refiere también a composiciones las cuales comprenden estos compuestos, y a procedimientos para tratar cáncer en mamíferos. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable o estereoisomero del mismo, en la que a es independientemente 0 o 1; b es independientemente 0 o 1; m es independientemente 0, 1 o 2; R1 está seleccionada de hidrogeno, OH, O-alquilo C1-6, -O-arilo, -O-heterociclilo, SH, -S-alquilo C1-6, -S-arilo, -S-heterociclilo, arilo, heterociclilo y NR8R9; dicho grupo alquilo, arilo y heterociclilo opcionalmente sustituidos con de uno a cinco sustituyentes, cada sustituyente independientemente seleccionados de R6; R2 y R3 están independientemente seleccionados de: hidrogeno, halo, (C=O)a-Ob-alquilo C1-10, (C=O)a-Ob-arilo, heterociclilo-(C=O)a-Ob, Ob- perfluoroalquilo C1-6, o cicloalquilo C3-8-(C=O)a-Ob, dichos alquilo, arilo, heterociclilo, y cicloalquilo opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados de R7; R4 y R5 están independientemente seleccionados de hidrogeno, alquilo C1-6, alquenilo C2-10, alquinilo C2-10, arilo, heterociclilo, OH, -O-alquilo C1-6, perfluoroalquilo C1-3, cada alquilo, alquenilo, alquinilo, heterociclilo y arilo opcionalmente sustituido con de uno a tres sustituyentes, cada sustituyente independientemente seleccionado de R6; R6 es independientemente: (C=O)a-Ob-alquilo C1-10, arilo-(C=O)a-Ob, alquenilo C2-10, alquinilo C2-10, heterociclilo-(C=O)a-Ob, CO2H, halo, CN, OH, Ob-perfluoroalquilo C1-6, Oa-(C=O)b-NR8R9, S(O)mRa, S(O)2NR8R9, OS(=O)Ra, oxo, CHO, (N=O)R8R9, o (C=O)a-Ob-cicloalquilo C3-8, dichos alquilo, arilo, alquenilo, alquinilo, heterociclilo, y cicloalquilo opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados de R7; R7 está independientemente seleccionado de: (C=O)a-Ob-alquilo C1-10, Ob-perfluoroalquilo C1-3, oxo, OH, halo, CN, alquenilo C2-10, alquinilo C2-10, (C=O)a-Ob-cicloalquilo C3-6, (C=O)a-Ob-alquileno C0-6-arilo, (C=O)a-Ob-alquileno C0-6-heterociclilo, (C=O)a-Ob-alquileno C0-6- N(Rb)2, C(O)Ra, alquileno C0-6-CO2Ra, C(O)H, alquileno C0-6-CO2H, C(O)N(Rb)2, S(O)mRa, y S(O)2NR8R9; dicho alquilo, alquenilo, alquinilo, cicloalquilo, arilo, y heterociclilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados de Rb, OH, alcoxi C1-6, halogeno, CO2H, CN, O(C=O)alquilo C1-6, oxo, y N(Rb)2; R8 y R9 se seleccionan independientemente de: H, (C=O)Ob-alquilo C1-10, (C=O)Ob-cicloalquilo C3-8, (C=O)Ob-arilo, (C=O)Ob-heterociclilo, alquilo C1-10, arilo, alquenilo C2-10, alquinilo C2-10, heterociclilo, cicloalquilo C3-8, SO2Ra, y (C=O)NRb2, dicho alquilo, cicloalquilo, arilo, heterociclilo, alquenilo, y alquinilo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados de R6, o R8 y R9 se pueden tomar conjuntamente con el nitrogeno al cual se han anclado para formar un heterociclo monocíclico o bicíclico con 5-7 miembros en cada anillo y que contienen opcionalmente, además del nitrogeno, uno o dos heteroátomos adicionales seleccionados de N, O y S, dicho heterociclo monocíclico o bicíclico opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados de R7; Ra está independientemente seleccionado de: alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, arilo, alquileno C1-6-arilo, heterociclilo y alquileno C1-6-heterociclilo; y Rb está independientemente seleccionado de: H, alquilo C1-6, arilo, alquileno C1-6-arilo, heterociclo, alquileno C1-6-heterociclilo, cicloalquilo C3-6, (C=O)O-alquilo C1-6, (C=O)-alquilo C1-6 o S(O)2Ra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81976406P | 2006-07-10 | 2006-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061804A1 true AR061804A1 (es) | 2008-09-24 |
Family
ID=38923821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102972A AR061804A1 (es) | 2006-07-10 | 2007-07-03 | Inhibidores de tirosina quinasa |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8222269B2 (es) |
| EP (1) | EP2049494B1 (es) |
| JP (2) | JP4203121B1 (es) |
| KR (1) | KR20090026187A (es) |
| CN (1) | CN101535268B (es) |
| AR (1) | AR061804A1 (es) |
| AU (1) | AU2007273081B2 (es) |
| BR (1) | BRPI0713941A2 (es) |
| CA (1) | CA2656578C (es) |
| CO (1) | CO6190518A2 (es) |
| CR (1) | CR10560A (es) |
| EC (1) | ECSP099051A (es) |
| ES (1) | ES2497493T3 (es) |
| GT (1) | GT200900004A (es) |
| HN (1) | HN2009000018A (es) |
| IL (1) | IL196337A0 (es) |
| MA (1) | MA30631B1 (es) |
| MX (1) | MX2009000410A (es) |
| NO (1) | NO20090608L (es) |
| PE (1) | PE20080275A1 (es) |
| RU (1) | RU2009104303A (es) |
| TW (1) | TW200813021A (es) |
| WO (1) | WO2008008310A2 (es) |
| ZA (1) | ZA200900019B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550478B2 (en) | 2005-06-23 | 2009-06-23 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
| US7893081B2 (en) | 2007-12-20 | 2011-02-22 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CN102036560A (zh) * | 2008-05-21 | 2011-04-27 | 巴斯夫欧洲公司 | 取代吡啶-4-基甲基磺酰胺 |
| CA2771338A1 (en) * | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Corp. | Crystalline hydrochloride salts of c-met kinase inhibitors |
| EP2482803B1 (en) * | 2009-09-30 | 2021-12-22 | Merck Sharp & Dohme (UK) Limited | Formulations for c-met kinase inhibitors |
| DK2571878T3 (en) | 2010-05-17 | 2019-02-11 | Indian Incozen Therapeutics Pvt Ltd | Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES |
| EP2588107A1 (en) | 2010-07-01 | 2013-05-08 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| CA2880896C (en) | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| EP3027654B1 (en) * | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
| WO2015017533A1 (en) * | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| EP4327879A3 (en) * | 2016-06-17 | 2024-05-22 | The Trustees of the University of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132137C (es) | 1963-04-24 | |||
| US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| IL98572A (en) | 1990-06-22 | 1995-07-31 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use |
| US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| HUP9801356A3 (en) | 1995-10-16 | 2000-07-28 | Kyowa Hakko Kogyo Kk | Triciclic (2-hydroxy-2-methyl-3,3,3-trifluoropropanoyl)-amino-benzoxepine, -benzothiepine, -benzocycloheptene, -indene derivatives and pharmaceutical compositions containing them |
| HUP9904067A2 (hu) | 1996-09-13 | 2000-05-28 | Schering Corporation | A G-protein-funkció gátlására és daganatos betegségek kezelésére alkalmazható triciklusos vegyületek |
| NZ334341A (en) | 1996-09-13 | 2001-01-26 | Schering Corp | Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| ATE363473T1 (de) | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| WO2003084931A1 (en) | 2002-04-02 | 2003-10-16 | Merck & Co., Inc. | 5h-benzo[4,5]cyclohepta[1,2-b]pyridine nmda/nr2b antagonists |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| JP2006151809A (ja) | 2002-12-26 | 2006-06-15 | Ube Ind Ltd | ベンゾシクロヘプタピリジン化合物 |
| CA2573103A1 (en) * | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| US7550478B2 (en) * | 2005-06-23 | 2009-06-23 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
| TW200738638A (en) | 2005-06-23 | 2007-10-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
-
2007
- 2007-07-02 TW TW096124020A patent/TW200813021A/zh unknown
- 2007-07-03 AR ARP070102972A patent/AR061804A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2007000877A patent/PE20080275A1/es not_active Application Discontinuation
- 2007-07-06 BR BRPI0713941-1A patent/BRPI0713941A2/pt not_active Application Discontinuation
- 2007-07-06 WO PCT/US2007/015675 patent/WO2008008310A2/en not_active Ceased
- 2007-07-06 MX MX2009000410A patent/MX2009000410A/es not_active Application Discontinuation
- 2007-07-06 RU RU2009104303/04A patent/RU2009104303A/ru not_active Application Discontinuation
- 2007-07-06 ES ES07810282.9T patent/ES2497493T3/es active Active
- 2007-07-06 AU AU2007273081A patent/AU2007273081B2/en not_active Ceased
- 2007-07-06 EP EP07810282.9A patent/EP2049494B1/en active Active
- 2007-07-06 KR KR1020097000538A patent/KR20090026187A/ko not_active Ceased
- 2007-07-06 CA CA2656578A patent/CA2656578C/en active Active
- 2007-07-06 JP JP2008536664A patent/JP4203121B1/ja not_active Expired - Fee Related
- 2007-07-06 CN CN2007800335075A patent/CN101535268B/zh not_active Expired - Fee Related
- 2007-07-06 US US12/309,149 patent/US8222269B2/en active Active
- 2007-07-09 US US11/827,109 patent/US8101603B2/en active Active
-
2008
- 2008-04-21 JP JP2008109902A patent/JP5245045B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196337A patent/IL196337A0/en unknown
- 2009-01-05 ZA ZA200900019A patent/ZA200900019B/xx unknown
- 2009-01-06 CO CO09000744A patent/CO6190518A2/es not_active Application Discontinuation
- 2009-01-07 HN HN2009000018A patent/HN2009000018A/es unknown
- 2009-01-09 GT GT200900004A patent/GT200900004A/es unknown
- 2009-01-09 EC EC2009009051A patent/ECSP099051A/es unknown
- 2009-01-14 CR CR10560A patent/CR10560A/es not_active Application Discontinuation
- 2009-02-09 MA MA31620A patent/MA30631B1/fr unknown
- 2009-02-09 NO NO20090608A patent/NO20090608L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061804A1 (es) | Inhibidores de tirosina quinasa | |
| AR045342A1 (es) | Inhibidores de quinesina mitotica | |
| AR058401A1 (es) | Pirimidinas sustituidas con sulfoximinas proceso para su produccion y uso de las mismas como farmacos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| PE20200796A1 (es) | Compuestos derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y composiciones que los comprenden | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| AR071609A1 (es) | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 | |
| AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| AR035626A1 (es) | Compuestos de indol inhibidores de tirosina quinasa, composicion farmaceutica, procedimiento para prepararla,y, uso de los compuestos en la preparación de medicamentos | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| ECSP088387A (es) | Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms | |
| EA201792394A3 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| AR077462A1 (es) | 3-oxo-2,3-dihidro-1h-isoindol-4-carboxamidas | |
| AR079529A1 (es) | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| RU2013118362A (ru) | Соединения имидазотриазинона | |
| DK1896421T3 (da) | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| PE20230253A1 (es) | Inhibicion de ezh2 en tratamientos combinados para el tratamiento del cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |